Related Experiment Video

Updated: May 7, 2026

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

Cangrelor versus clopidogrel in percutaneous coronary intervention: a systematic review and meta-analysis

Anil Pandit1, Madan Raj Aryal, Aashrayata Aryal Pandit

  • 1Division of Cardiovascular Diseases, Mayo Clinic, Scottsdale, AZ, USA.

Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology
|October 2, 2013
PubMed

Insights

Cangrelor and clopidogrel show similar efficacy in reducing ischemic events after percutaneous coronary intervention (PCI). However, cangrelor demonstrated a lower risk of stent thrombosis and Q-wave myocardial infarction.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Cangrelor is an antiplatelet agent used in percutaneous coronary intervention (PCI).
  • Previous studies on cangrelor in PCI have yielded mixed results.

Purpose of the Study:

  • To review evidence comparing cangrelor and clopidogrel efficacy in reducing ischemic endpoints within 48 hours in PCI patients.
  • To analyze data from large randomized trials to assess cangrelor's effectiveness.

Main Methods:

  • Meta-analysis of three large clinical trials involving 25,107 participants.
  • Comparison of cangrelor versus clopidogrel regarding composite efficacy endpoints and bleeding events.

Main Results:

  • No significant difference in the primary composite endpoint (death, MI, ischemia-driven revascularization) at 48 hours between cangrelor and clopidogrel (OR 0.94; 95% CI: 0.77-1.14).
  • Similar rates of severe or life-threatening bleeding between the two agents (OR 1.21; 95% CI: 0.70-2.12).
  • Lower risk of stent thrombosis (OR 0.59; 95% CI: 0.43-0.81), Q-wave myocardial infarction (OR 0.53; 95% CI: 0.30-0.92), and ischemia-driven revascularization (OR 0.71; 95% CI: 0.52-0.98) with cangrelor.

Conclusions:

  • Cangrelor and clopidogrel show comparable efficacy for the primary composite endpoint in PCI patients.
  • Cangrelor is associated with a reduced risk of stent thrombosis, Q-wave MI, and ischemia-driven revascularization.
  • Cangrelor presents a viable alternative to clopidogrel during PCI procedures.
Abstract

More Related Videos

Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control05:41

Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control

Published on: December 16, 2022

Fully Endoscopic Mitral Valve Repair with Percutaneous Cannulation of Groin Vessels08:12

Fully Endoscopic Mitral Valve Repair with Percutaneous Cannulation of Groin Vessels

Published on: May 26, 2023

Related Concept Videos

Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...